Extensions

Analysis of Patent Term and Related Applications for U.S. Patent No. 12,031,784

As of April 26, 2026, an analysis of the prosecution history and status of U.S. Patent No. 12,031,784 ("the '784 patent") provides the following details regarding its term, related applications, and family members.

Patent Term and Expiration

• Filing Date: The underlying non-provisional application, US 18/052,606, was filed on November 4, 2022.
• Patent Term: The standard term for a U.S. patent is 20 years from the earliest non-provisional filing date.
• Patent Term Adjustment (PTA): Based on a review of the patent's file history, there has been no Patent Term Adjustment granted by the USPTO. The time from filing (November 4, 2022) to issuance (July 9, 2024) was less than three years, and there appear to be no other prosecution delays that would trigger a PTA under 35 U.S.C. § 154.
• Patent Term Extension (PTE): There are no Patent Term Extensions under 35 U.S.C. § 156. PTE is typically granted for delays caused by regulatory review, such as by the FDA, and is not applicable to this patent's subject matter.
• Projected Expiration Date: With a filing date of November 4, 2022, and no term adjustments, the projected expiration date for U.S. Patent No. 12,031,784 is November 4, 2042.

Continuity and Related Applications

• Priority Application: The '784 patent properly claims priority to U.S. Provisional Application No. 63/276,090, which was filed on November 5, 2021. The non-provisional application was filed within the one-year period allowed.

• Continuation or Divisional Applications: A search of USPTO records indicates that, as of this date, no continuation or divisional applications have been filed that claim a direct benefit to the '784 patent or its parent application (US 18/052,606).

• Patent Family Members: The patent family for this invention is currently limited to the United States. It consists of the U.S. provisional application and the issued '784 patent. There are no foreign counterpart applications claiming priority to the U.S. application. The patent is one of several related to forced reset triggers assigned to ABC IP, LLC, but it does not share a direct priority claim with the others, such as U.S. Patent No. 12,038,247.